why choose us

First received: August 31, 2023

Clinical Trial: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Soli

Brief Summary: CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

Read more